The aim of this study is to assess the impact of the diagnosis of arterial hypertension on the mortality by any cause and due to cardiovascular disorders in individuals monitored in the community throughout a period of no less than 10 years.
– Assess the differences in death by any cause and due to cardiovascular disorders after 10 years of monitoring subjects with arterial hypertension grades I, II and III as per the European Guidelines.
– Evaluate the impact of blood pressure control level on total mortality and due to cardiovascular disorders.
– Evaluate the impact of different factors on global mortality and due to cardiovascular disorders in patients with arterial hypertension (adjusted by control level):
o Comorbidity: defined as the presence of diabetes, cardiovascular disease, obesity, smoking, or previous damage to the target organ at the time of diagnosis of arterial hypertension.
o Family of drugs used in the treatment: ACEI, ARA2, diuretics, calcium channel blockers, beta-blockers, alpha-blockers, or different combinations of these drugs.
o Socioeconomic level (measured through the deprivation index of the health centre).
– Assess the relationship between the use of healthcare services (measured through the number of visits to the physician and the nurse, and the annual time devoted to the patient at the health centre) and total and cardiovascular mortality in hypertensive patients.
– Analyse the difference in the rate of cardiovascular events (chronic kidney disease, ischaemic heart disease, cerebrovascular disease, peripheral arterial disease) among subjects with arterial hypertension grade I, II and III as per the European Guidelines.
Multicentre retrospective cohort study. The exposure cohort will be defined by those subjects over 18 years of age who have a “de novo” diagnosis of non-secondary HTN in 2005/2006. The cohort of unexposed subjects will be created including one subject without HTN diagnosis in the same period, per exposed subject.
These subjects will be paired by health centre, age (same decade of life), and presence of DM or CV disease (chronic kidney failure, acute stroke, ischaemic heart disease or peripheral arterial disease) at the time of inclusion in the study. The follow-up time shall extend until the last visit, death or loss, which offers a maximum observation time of at least 12 years for the last subject included.
The cohorts will be created based on data from all the health centres of three Autonomous Communities: Madrid, the Basque Country and the Canary Islands.